Trinity Biotech plc is an Ireland-based commercial stage biotechnology company. The Company is focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market and has also entered the wearable biosensor industry. It intends to develop a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Its products are used to detect infectious diseases and to quantify the level of Hemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. The Company, through EpiCapture Limited, is also developing a non-invasive test for monitoring the risk of aggressive prostate cancer. The Company sells its products direct in the United States and through a network of international distributors.
企業コードTRIB
会社名Trinity Biotech PLC
上場日Oct 21, 1992
最高経営責任者「CEO」Mr. John Gillard
従業員数- -
証券種類Depository Receipt
決算期末Oct 21
本社所在地Ida Business Park, Bray, Co Wicklow
都市DUBLIN
証券取引所NASDAQ Global Select Consolidated
国Ireland
郵便番号18
電話番号01135312955111
ウェブサイトhttps://www.trinitybiotech.com/
企業コードTRIB
上場日Oct 21, 1992
最高経営責任者「CEO」Mr. John Gillard
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし